Cancer resistance in transgenic mice expressing the SAC module of Par-4

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9276-9285

  Zhao, Yanming ^a   Burikhanov, Ravshan ^a   Qiu, Shirley ^a   Lele, Subodh M ^d   Jennings, C Darrell ^a   Bondada, Subbarao ^a,b,c   Spear, Brett ^a,b,c   Rangnekar, Vivek M ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN PAR 4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; AGING; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL IMMORTALIZATION; CONTROLLED STUDY; LIFESPAN; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREEN FLUORESCENT PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PROTEINASE-ACTIVATED; RECOMBINANT FUSION PROTEINS;

EID: 35148859307     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2124     Document Type: Article

References (30)

1. Sells SF, Wood DP, Jr., Barve SSJ, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994;5:457-66.
2. Sells SF, Han S-S, Muthukkumar S, et al. Expression and function of the leucine zipper protein par-4 in apoptosis. Mol Cell Biol 1997;17:3823-32.
3. El-Guendy N, Rangnekar VM. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 2003;283:51-66.
4. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. Identification of a unique core domain of Par-4 sufficient for selective apoptosis-induction in cancer cells. Mol Cell Biol 2003;23:5516-25.
5. Chakraborty M, Qiu SG, Vasudevan K, Rangnekar VM. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001;61:7255-63.
6. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4by protein kinase A is critical for apoptosis. Mol Cell Biol 2005;25:1146-61.
7. Garcia-Cao I, Duran A, Collado M, et al. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005;6:577-83.
8. Johnstone RW, Tommerup N, Hansen C, Vissing H, Shi Y. Mapping of the human PAWR (par-4) gene to chromosome 12q21. Genomics 1998;53:241-3.
9. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, et al. Inactivation of the candidate tumor suppressor Par-4 in endometrial cancer. Cancer Res 2007;67:1927-34.
10. Cook J, Krishnan S, Ananth S, et al. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 1999;18:1205-8.
11. Goswami A, Burikhanov R, de Thonel A, et al. Binding and phosphorylation of Par-4 by Akt is essential for cancer cell survival. Mol Cell 2005;20:33-44.
12. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-9.
13. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
14. Perincheri S, Dingle RW, Peterson ML, Spear BT. Hereditary persistence of a-fetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the Zhx2 gene. Proc Natl Acad Sci U S A 2005;102:396-401.
15. Joshi-Barve SS, Rangnekar VV, Sells SF, Rangnekar VM. Interleukin-1-inducible expression of gro-β via NF-κB activation is dependent upon tyrosine kinase signaling. J Biol Chem 1993;268:18018-29.
16. Nalca A, Qiu SG, El-Guendy N, Krishnan S, Rangnekar VM. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem 1999;274:29976-83.
17. Rao GN, Haseman JK, Grumbein S, Crawford DD, Eustis SL. Growth, body weight, survival, and tumor trends in (C57BL/6 x C3H/HeN) F1 (B6C3F1) mice during a nine-year period. Toxicol Pathol 1990;18:71-7.
18. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30.
19. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31:14-24.
20. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120:513-22.
21. Balmain A. Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell 2002;108:145-52.
22. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. Allelic variation in human gene expression. Science 2002;297:1143.
23. Lo HS, Wang Z, Hu Y, et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003;13:1855-62.
24. Yan H, Zhou W. Allelic variations in gene expression. Curr Opin Oncol 2004;16:39-43.
25. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, et al. 'Super p53′ mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002;21:6225-35.
26. Matheu A, Pantoja C, Efeyan A, et al. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev 2004;18:2736-46.
27. Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002;415:45-53.
28. Maier B, Gluba W, Bernier B, et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004;18:306-19.
29. Diaz-Meco MT, Municio MM, Frutos S, et al. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 1996;86:777-86.
30. Affar el B, Luke MP, Gay F, et al. Targeted ablation of Par-4reveals a cell type-specific susceptibility to apoptosis-inducing agents. Cancer Res 2006;66:3456-62.